vs
莫德纳（MRNA）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是莫德纳的1.3倍（$1.3B vs $1.0B），莫德纳净利率更高（-19.7% vs -63.1%，领先43.4%），Rivian Automotive, Inc.同比增速更快（-25.8% vs -45.4%），莫德纳自由现金流更多（$-880.0M vs $-1.1B），过去两年Rivian Automotive, Inc.的营收复合增速更高（3.3% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
MRNA vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.3倍
$1.0B
营收增速更快
RIVN
高出19.6%
-45.4%
净利率更高
MRNA
高出43.4%
-63.1%
自由现金流更多
MRNA
多$264.0M
$-1.1B
两年增速更快
RIVN
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.3B |
| 净利润 | $-200.0M | $-811.0M |
| 毛利率 | 79.6% | 9.3% |
| 营业利润率 | -25.6% | -64.8% |
| 净利率 | -19.7% | -63.1% |
| 营收同比 | -45.4% | -25.8% |
| 净利润同比 | -1638.5% | -9.0% |
| 每股收益（稀释后） | $-0.51 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNARIVN
| Q4 25 | — | $1.3B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $966.0M | $1.7B | ||
| Q3 24 | $1.9B | $874.0M | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
净利润MRNARIVN
| Q4 25 | — | $-811.0M | ||
| Q3 25 | $-200.0M | $-1.2B | ||
| Q2 25 | — | $-1.1B | ||
| Q1 25 | — | $-545.0M | ||
| Q4 24 | $-1.1B | $-744.0M | ||
| Q3 24 | $13.0M | $-1.1B | ||
| Q2 24 | — | $-1.5B | ||
| Q1 24 | — | $-1.4B |
毛利率MRNARIVN
| Q4 25 | — | 9.3% | ||
| Q3 25 | 79.6% | 1.5% | ||
| Q2 25 | — | -15.8% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | 23.5% | 9.8% | ||
| Q3 24 | 72.4% | -44.9% | ||
| Q2 24 | — | -38.9% | ||
| Q1 24 | — | -43.8% |
营业利润率MRNARIVN
| Q4 25 | — | -64.8% | ||
| Q3 25 | -25.6% | -63.1% | ||
| Q2 25 | — | -85.5% | ||
| Q1 25 | — | -52.8% | ||
| Q4 24 | -129.0% | -38.1% | ||
| Q3 24 | -3.8% | -133.8% | ||
| Q2 24 | — | -118.7% | ||
| Q1 24 | — | -123.3% |
净利率MRNARIVN
| Q4 25 | — | -63.1% | ||
| Q3 25 | -19.7% | -75.3% | ||
| Q2 25 | — | -85.7% | ||
| Q1 25 | — | -44.0% | ||
| Q4 24 | -115.9% | -42.9% | ||
| Q3 24 | 0.7% | -125.9% | ||
| Q2 24 | — | -125.8% | ||
| Q1 24 | — | -120.1% |
每股收益（稀释后）MRNARIVN
| Q4 25 | — | $-0.66 | ||
| Q3 25 | $-0.51 | $-0.96 | ||
| Q2 25 | — | $-0.97 | ||
| Q1 25 | — | $-0.48 | ||
| Q4 24 | $-2.91 | $-0.67 | ||
| Q3 24 | $0.03 | $-1.08 | ||
| Q2 24 | — | $-1.46 | ||
| Q1 24 | — | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $6.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.3B | $4.6B |
| 总资产 | $12.1B | $14.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MRNARIVN
| Q4 25 | — | $6.1B | ||
| Q3 25 | $1.1B | $7.1B | ||
| Q2 25 | — | $7.5B | ||
| Q1 25 | — | $7.2B | ||
| Q4 24 | $1.9B | $7.7B | ||
| Q3 24 | $1.6B | $6.7B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.9B |
总债务MRNARIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.5B | ||
| Q1 24 | — | $4.4B |
股东权益MRNARIVN
| Q4 25 | — | $4.6B | ||
| Q3 25 | $9.3B | $5.1B | ||
| Q2 25 | — | $6.1B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | $10.9B | $6.6B | ||
| Q3 24 | $11.9B | $5.9B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $8.1B |
总资产MRNARIVN
| Q4 25 | — | $14.9B | ||
| Q3 25 | $12.1B | $15.2B | ||
| Q2 25 | — | $15.6B | ||
| Q1 25 | — | $15.5B | ||
| Q4 24 | $14.1B | $15.4B | ||
| Q3 24 | $15.8B | $14.3B | ||
| Q2 24 | — | $15.4B | ||
| Q1 24 | — | $15.7B |
负债/权益比MRNARIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $-1.1B |
| 自由现金流率自由现金流/营收 | -86.6% | -89.0% |
| 资本支出强度资本支出/营收 | 3.2% | 36.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $-2.5B |
8季度趋势，按日历期对齐
经营现金流MRNARIVN
| Q4 25 | — | $-681.0M | ||
| Q3 25 | $-847.0M | $26.0M | ||
| Q2 25 | — | $64.0M | ||
| Q1 25 | — | $-188.0M | ||
| Q4 24 | $825.0M | $1.2B | ||
| Q3 24 | $-1.6B | $-876.0M | ||
| Q2 24 | — | $-754.0M | ||
| Q1 24 | — | $-1.3B |
自由现金流MRNARIVN
| Q4 25 | — | $-1.1B | ||
| Q3 25 | $-880.0M | $-421.0M | ||
| Q2 25 | — | $-398.0M | ||
| Q1 25 | — | $-526.0M | ||
| Q4 24 | $303.0M | $856.0M | ||
| Q3 24 | $-1.7B | $-1.2B | ||
| Q2 24 | — | $-1.0B | ||
| Q1 24 | — | $-1.5B |
自由现金流率MRNARIVN
| Q4 25 | — | -89.0% | ||
| Q3 25 | -86.6% | -27.0% | ||
| Q2 25 | — | -30.5% | ||
| Q1 25 | — | -42.4% | ||
| Q4 24 | 31.4% | 49.4% | ||
| Q3 24 | -92.2% | -131.9% | ||
| Q2 24 | — | -89.6% | ||
| Q1 24 | — | -126.5% |
资本支出强度MRNARIVN
| Q4 25 | — | 36.0% | ||
| Q3 25 | 3.2% | 28.7% | ||
| Q2 25 | — | 35.5% | ||
| Q1 25 | — | 27.3% | ||
| Q4 24 | 54.0% | 18.9% | ||
| Q3 24 | 8.1% | 31.7% | ||
| Q2 24 | — | 24.4% | ||
| Q1 24 | — | 21.1% |
现金转化率MRNARIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -120.46× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
